Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Insulin Delivery, Other

Insulet Omnipod 5 Receives CE Mark; Novo Nordisk and Octagon Therapeutics Collaboration for Inflammatory Disease Targets; Diamyd Presents Updated 12-month Results from Ph2 GADinLADA Trial; EASD 2022 Key Press Releases (Sept 20)

Here is a brief preview of this blast: On the second day of EASD 2022, three key press releases were observed from Insulet, Novo Nordisk, and Diamyd. Below FENIX provides insights and context for the respective announcements.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.